# Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC)

> **NCT00822393** · PHASE3 · COMPLETED · sponsor: **medac GmbH** · enrollment: 570 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Myelodysplastic Syndrome

## Interventions

- **DRUG:** Busulfan
- **DRUG:** Treosulfan

## Key facts

- **NCT ID:** NCT00822393
- **Lead sponsor:** medac GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11-24
- **Primary completion:** 2018-01-25
- **Final completion:** 2018-01-25
- **Target enrollment:** 570 (ACTUAL)
- **Last updated:** 2020-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00822393

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00822393, "Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00822393. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*